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PEffects of Multiple Oral Doses of an A1 Adenosine
Antagonist, BG9928, in Patients With Heart Failure
Results of a Placebo-Controlled, Dose-Escalation Study
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Objectives This study sought to assess the pharmacokinetics and clinical effects of oral BG9928 in heart failure (HF) patients.
Background Declining renal function during HF treatment is associated with poor outcomes. BG9928, a selective inhibitor of
the A1 adenosine receptor, is proposed to cause natriuresis without causing a decline in renal function.
Methods A randomized, double-blind, placebo-controlled study was conducted in patients with HF and systolic dysfunction
who were receiving standard therapy. Patients were randomized to receive BG9928 (3, 15, 75, or 225 mg) or
placebo orally for 10 days. The primary end point was change in sodium excretion. Changes in potassium excre-
tion, creatinine clearance, and body weight also were evaluated.
Results A total of 50 patients were studied. BG9928 increased sodium excretion compared with placebo, and natriuresis
was maintained over 10 days with little kaliuresis. A linear trend in dose response was observed on day 1 (p 
0.04) but not on days 6 or 10. Adjusted creatinine clearance was unchanged over the 10 days. Patients who
received 15, 75, or 225 mg of BG9928 had a reduction in body weight compared with placebo (0.6, 0.7,
0.5, vs. 0.3 kg, respectively) at the end of study. BG9928 was well tolerated. The pharmacokinetic profile of
BG9928 was consistent with once-daily dosing.
Conclusions Oral BG9928 over the dose range of 3 to 225 mg/day produced significant increases in sodium excretion in pa-
tients with stable HF without causing kaliuresis or reducing renal function. (J Am Coll Cardiol 2007;50:600–6)
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August 14, 2007:600–6 Oral BG9928 in HFany patients with heart failure (HF) have underlying renal
unction abnormalities, and renal function often further
eteriorates during treatment (1), especially in those taking
iuretics and inhibitors of the renin-angiotensin system
2–4). Worsening renal function is associated with higher
ortality and higher costs in hospitalized patients with HF
5–10). Consequently, preserving renal function in these
atients may improve outcomes.
Adenosine modulates glomerular filtration by several
echanisms and may contribute to renal dysfunction in
atients with HF by reducing glomerular filtration (11,12).
elective A1 adenosine receptor blockade decreases afferent
rteriole tone, increases urine flow, and causes natriuresis (13).
n patients with HF treated with single intravenous doses of
urosemide alone, the adenosine blocker alone, and the com-
ination, the addition of the A1 adenosine receptor antagonist
revented reductions in renal function associated with furo-
emide use (3,14). BG9928 (Biogen Idec, Cambridge, Mas-
achusetts) is an orally active, potent, and selective inhibitor of
he A1 adenosine receptor (15), and its use in patients receiving
tandard therapy for HF, including diuretics and angiotensin-
onverting enzyme (ACE) inhibitors, is being investigated.
This study was designed to evaluate the pharmacokinetics
nd effects on volume status and renal function of multiple
ral doses of BG9928 given over 10 days.
ethods
atient population. Patients were eligible for the study if
hey had a diagnosis of HF for at least 3 months before
creening, had stable New York Heart Association (NYHA)
unctional class II to IV symptoms, and an ejection fraction of
40% documented within the past 12 months. Additional
nclusion criteria included age between 18 and 80 years, weight
50 kg, and body mass index 19 kg/m2. All patients were
creened within 28 days of study drug administration and had
o be on a stable medical regimen for at least 2 weeks, including
n ACE inhibitor or an angiotensin II receptor blocker (ARB).
Figure 1 Schematic Illustration of Study Design and Assessme
Timing and hourly intervals for assessments are described in the text. *Inpatient s
lected on day 16. ‡Assessment hourly intervals at baseline: 0 to 4, 4 to 8, 8 to 1
24. §Collection hourly intervals at baseline: 0 to 4, 4 to 8, 8 to 12, and 12 to 24
32 h after last dose. Collection hourly intervals at baseline: 0, 4, 8, 12, and 2
NYHA  New York Heart Association; PGA  Physician’s Global Assessment; PO hose who required more than
hort-acting nitrates to treat an-
ina or had unstable angina were
xcluded. Patients with renal im-
airment (i.e., 3 g proteinuria in
24-h period or creatinine clear-
nce [CrCl] 30 ml/min/1.73
2), potential for recent renal in-
ury (i.e., significant episode of hy-
otension or any surgery requiring
eneral anesthesia, coronary artery
ypass graft, or percutaneous cor-
nary intervention within 8 weeks
efore screening, any dose of ra-
iologic contrast agents or amino-
lycosides within 4 weeks before
creening, treatment with nephro-
oxic drugs within 2 weeks before
creening, or any other agents capable of affecting renal
unction within 24 h before baseline), history of urinary
bstruction, myocardial infarction or stroke within the prior
months, or other serious systemic disease were not eligible
or study entry. Written informed consent was obtained
rom each patient before study entry. The study protocol
as approved by the institutional review board of each study
ite and was conducted in accordance with the Declaration
f Helsinki.
tudy design and treatment. This was a multicenter,
andomized, double-blind, placebo-controlled, multiple-
ose, dose-escalation study in patients with stable HF.
aily oral doses of BG9928 were administered for 10 days
uring this study. Patients were evaluated in the hospital
nd clinic as shown in Figure 1. Postdosing clinic visits were
equired on days 12, 14, and 16, and telephone follow-up
as performed on day 38.
Patients were enrolled by increasing dose cohorts and
ere randomized to receive BG9928 or placebo within each
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin II
receptor blocker
AUC  area under the
concentration time curve
Cmax  peak concentration
CrCl  creatinine clearance
ECG  electrocardiogram
HF  heart failure
NYHA  New York Heart
Association
t½  elimination half-life
tmax  time to Cmax
ntil 4 h after second and seventh dose and 32 h after tenth dose. †Also col-
12 to 24; on days 1, 6, 10, and 16: 0 to 2, 2 to 4, 4 to 8, 8 to 12, and 12 to
ys 1, 6, 10: 0 to 2, 2 to 4, 4 to 8, 8 to 12, and 12 to 24; on day 11: 28 h to
days 1, 6, and 10: 2, 4, 8, and 12; on days 4 and 8: 0; on day 11: 4 and 8.
os (by mouth).nts
tays u
2, and
; on da
4; on
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Oral BG9928 in HF August 14, 2007:600–6ohort using a centralized randomization process (interac-
ive voice response system) with a simple randomization
cheme and no stratification factors. The site pharmacist
as not blinded and prepared all doses of study medication;
ll other study personnel remained blinded. Doses of all
rescription medication and nonprescription medication
ere to remain stable for at least 2 weeks before day 1 and
hrough day 16. Patients were not to receive treatment with
ephrotoxic drugs within 2 weeks before screening or agents
apable of affecting renal function within 24 h before
aseline day until day 16. Patients were not permitted to
onsume medications, foods, or beverages containing caf-
eine 8 h before until 8 h after the oral dose was taken on
aseline days 1, 6, and 10. Also, on inpatient assessment
ays, patients were not permitted to take other medications
rom 8 h before study drug administration through the 8-h
ostdose time point. Permitted medications were reinstated
fter the 8-h postdose evaluations.
Alcohol was not permitted 48 h before baseline, and
atients could not use tobacco products within the 24 h
efore baseline through day 16. On inpatient assessment
ays (baseline days 1, 6, and 10) all patients fasted before
tudy drug administration through 4 h after dosing.
fficacy assessments. The primary measures of efficacy
ere changes in urinary sodium excretion and urine volume.
dditional measures assessed were urinary potassium excre-
ion, adjusted CrCl, body weight, the Cody Edema Score
2), physician global assessment, and NYHA functional
lassification. Basic urine chemistry analysis (sodium, potas-
ium, calcium, phosphate, creatinine) was performed on
rine samples collected at baseline and on days 1, 6, 10, and
6. Urine volumes were recorded for urine collections at
aseline and on days 1, 6, 10, and 11. Blood samples were
ollected for blood chemistry analysis at baseline and on
ays 1, 4, 6, 8, 10, and 11. The frequency and timing of
emographics and Baseline Disease Characteristics
Table 1 Demographics and Baseline Disease Characteristics
3 mg (n  10) 15 mg (n 
Male, n (%) 9 (90) 8 (80)
Age, yrs (mean  SD) 56.1  8.9 49.5  11
Race, n (%)
Black 3 (30) 3 (30)
White 5 (50) 6 (60)
Hispanic 2 (20) 1 (10)
Height, cm (mean  SD) 174.4  9.7 173.8  9.2
Weight, kg (mean  SD) 94.1  9.0 99.7  22
BMI, kg/m2 (mean  SD) 31.2  4.7 32.9  6.9
Concomitant medication, n (%)
ACE inhibitor/ARB 10 (100) 10 (100)
Diuretic 7 (70) 9 (90)
Adjusted creatinine clearance,*
ml/min/1.73 m2 (mean  SD)
108.7  30.6 (n  8) 107.8  42.3 (Over 2 h to 24 h.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BMI  body mass index.ssessments are summarized in Figure 1. All laboratory
nalyses were conducted at a central location, Covance
entral Laboratory Services.
Adjusted CrCl was calculated as CrCl  1.73/body surface
rea, where body surface area  (height [in cm])0.725 
weight [in kg])0.425 0.007184. Body weight was determined
t screening, at baseline, and on days 1, 6, and 10. The Cody
dema Score was evaluated at screening; at baseline; on
ays 1, 6, and 10 (predose and at 4 h); and on the other days
t the time of study drug administration. The physician
lobal assessment and NYHA functional class determina-
ion were made at baseline and on day 10. Physician global
ssessment was performed using a visual analog scale of 0 to
00; a positive change from baseline to day 10 reflects
mprovement in status.
harmacokinetic evaluation. Blood was collected for
harmacokinetic analysis on days 1, 6, and 10 (predose, 30
in, 60 min, 90 min, 2 h, 2.5 h, 3 h, 4 h, 6 h, 8 h, 10 h,
2 h, and 24 h); days 2 and 7 (predose); days 4 and 8 (0 h);
ay 11 (4 h and 8 h); and days 12, 14, and 16 (all at 0 h).
eak concentration (Cmax), time to Cmax (tmax), area under
he concentration time curve (AUC), uncorrected clearance,
nd elimination half-life (t1/2) were calculated noncompart-
entally using WinNonlin Professional software (version
.1, Pharsight Corp., Mountain View, California).
afety assessments. All patients who received at least 1
ose of study drug were included in the safety analysis.
ssessments included physical examinations, an examina-
ion for HF, and monitoring of vital signs. An electrocar-
iogram (ECG) was performed at the screening visit, on
ays 1, 6, and 10 at 5 to 60 min before dosing and at 2.5 h
fter dosing, and on days 2, 7, 11, and 12 at the start of the
isit (0 h). On hospital admission (day 1), all patients
eceived continuous telemetry monitoring. Adverse events,
linically significant abnormal laboratory results, medical
928 Dose
Placebo (n  10)75 mg (n  10) 225 mg (n  10)
7 (70) 9 (90) 8 (80)
56.3  12.8 52.9  11.6 52.5  16.1
0 (0) 4 (40) 4 (40)
7 (70) 3 (30) 6 (60)
3 (30) 3 (30) 0 (0)
171.5 10.0 173.6  10.7 173.2  8.3
86.5  11.4 109.5  30.3 94.8  15.2
29.5  4.3 36.0  7.9 31.8  5.7
10 (100) 10 (100) 10 (100)
10 (100) 9 (90) 10 (100)
97.0  44.6 (n  10) 134.0  39.0 (n  7) 102.9  33.8 (n  10)BG9
10)
.0
.6
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August 14, 2007:600–6 Oral BG9928 in HFiagnosis noted by medical personnel, and symptoms re-
orted by the patient (regardless of relationship to study
rug) were monitored continually throughout the study.
tatistical analyses. The primary end point for determina-
ion of sample size was the change from baseline in sodium
xcretion over 0 to 8 h. The 0 to 8-h interval was evaluated
s the primary end point because patients resumed their
sual concomitant medications 8 h after study drug dosing.
sample size of 8 patients per treatment group was
alculated to provide 90% power to show a dose response
fter both the first and the last dose, based on a 2-sided test
or linear trend with a 5% type I error. Ten patients were
lanned for each of 4 dose cohorts (3, 15, 75, and 225 mg
f active drug), with 2 patients receiving matching placebo
n the 3- and 15-mg cohorts and 3 receiving placebo in the
5- and 225-mg cohorts.
The analysis population for evaluating pharmacodynamic
nd efficacy data was defined for all patients who received
tudy drug, had at least 1 postdose assessment, and had no
ajor protocol violations. An analysis of covariance adjust-
ng for the baseline value of each parameter was used to test
Figure 2 Cumulative Urinary Sodium Excretion During Dosing
Cumulative urinary sodium excretion (mEq) over the interval of 0 to 8 h at
baseline and after placebo or BG9928 administration on days 1, 6, and 10.
*p  0.05 versus placebo. †p  0.055 versus placebo. n  10/group except
for 15- and 75-mg dose groups on day 10 (n  9/group).
hange From Baseline in Urine Volume for the 0 to 8 h After Study
Table 2 Change From Baseline in Urine Volume for the 0 to 8 h
3 mg (n  10) 15 mg (n
Day 1
Mean (SD) change from baseline, ml 261.6 (585.8) 691.5 (76
p value versus placebo 0.318 0.005
Day 6
Mean (SD) change from baseline, ml 169.1 (372.3) 227.4 (25
p value versus placebo 0.603 0.231
Day 10
Mean (SD) change from baseline, ml 235.6 (482.7) 396.8 (53
p value versus placebo 0.148 0.006Data were available for 9 patients in the 75-mg treatment group on day 10.or a linear trend in dose response and also to compare each
G9928 dose group with the placebo group in change from
aseline in sodium excretion, urine volume, potassium
xcretion, CrCl, and weight. Because this was an explor-
tory study, no adjustment was made to the type I error rate
or multiple comparisons.
esults
t the 8 study sites, 53 patients were enrolled. Of these, 50
atients were randomized and received study medication
nd 3 withdrew before study drug administration. The
istributions of gender, age, and race were similar among
he dose groups (Table 1). All patients received concomitant
CE inhibitor or ARB therapy, and 70% to 100% of
atients across the treatment groups received diuretics
uring the study (Table 1). Other commonly received
oncomitant medications included beta-blockers (80%),
igoxin (58%), and spironolactone (24%).
fficacy assessments. URINARY MEASURES. Urinary so-
ium excretion was increased in patients who received
G9928 compared with baseline and those who received
lacebo, when measured over the first 8 h on day 1 (Fig. 2).
he mean changes from baseline on day 1 in the 3-, 15-,
nd 225-mg groups were statistically significantly different
rom placebo (marginally significant at 75 mg). The test for
inear trend in dose response was statistically significant
p  0.04), although the maximum change from baseline on
ay 1 occurred with the 15-mg dose without evidence of an
ncreased effect at higher doses (Fig. 2). The natriuretic effect
as maintained over the 10-day dosing period in all BG9928
ose groups. However, the linear trend in dose response was no
onger evident on days 6 or 10, and the 3-mg dose seemed to
ave an equal effect to the higher doses.
Urine volume increased from baseline for all dose groups
uring the 0 to 8-h interval on day 1 and was greatest with the
5-mg dose group (p 0.005) (Table 2). The results for urine
olume were similar to those for cumulative sodium excretion,
ut because of increased variability, the urine volume results
id not reach statistical significance at some time points when
odium excretion was significant (Fig. 2, Table 2).
Administration on Days 1, 6, and 10
r Study Drug Administration on Days 1, 6, and 10
G9928 Dose
Placebo (n  10)75 mg (n  10*) 225 mg (n  10)
295.7 (674.9) 177.1 (989.7) 334.9 (760.6)
0.123 0.113 —
371.0 (703.3) 27.0 (479.4) 141.9 (644.0)
0.047 0.509 —
49.7 (641.3) 25.8 (385.2) 271.8 (600.0)
0.363 0.165 —Drug
Afte
B
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Oral BG9928 in HF August 14, 2007:600–6On days 1, 6, and 10, there was no significant linear trend
or dose response for the change from baseline in cumulative
otassium excretion over the 0 to 8-h interval (Fig. 3). The
ncrease from baseline in potassium excretion was higher
han the placebo group to a statistically significant degree in
everal dosing groups and dosing days. However, these
ifferences were relatively small (19 mEq over the 0 to 8-h
nterval) and are unlikely to be of clinical importance.
Similarly, no significant linear trend in dose response was
dentified for adjusted CrCl over the 2- to 8-h interval or
he 2- to 24-h interval. The CrCl was relatively unaffected
y BG9928 administration (Fig. 4). There were no signif-
cant reductions in adjusted CrCl in any treatment group.
Figure 4 Change in Renal Function During Dosing
Absolute change from baseline in adjusted creatinine clearance (CrCl) (ml/min/
1.73 m2) for the interval of 2 to 24 h after placebo or BG9928 administration
on days 1, 6, and 10. *p  0.05 versus placebo. n  7 to 10 per group.
Figure 3 Cumulative Urinary
Potassium Excretion During Dosing
Cumulative urinary potassium excretion (mEq) over the interval of 0 to 8 h at
baseline and after placebo or BG9928 administration on days 1, 6, and 10.
*p  0.05 versus placebo. n  10/group except for 15- and 75-mg dose
groups on day 10 (n  9/group).nLINICAL MEASURES. The mean changes in body weight
rom day 1 to day 11 are shown in Figure 5. The placebo
roup gained an average of 0.3 kg in weight, whereas there
as a trend toward a decrease in weight in the BG9928 (0.7
g in the 75-mg group; p  0.082, unadjusted). No linear
rend for dose response was found for BG9928 dose and
eight change.
Although there were no significant differences in clinical
tatus, HF patients treated with BG9928 showed favorable
irectional trends, in other measures of clinical status,
ncluding the Cody Edema Score, physician global assess-
ent, and NYHA functional class. The mean change from
ay 1 to day 11 in the Cody Edema Score was 0 in the
lacebo group, 0.4 in the 3-mg group, 0.6 in the 15-mg
roup, 0.6 in the 75-mg group, and 0.4 in the 225-mg
roup, where a negative change indicates an improvement in
F signs. The mean change from baseline in the physician
lobal assessment showed a worsened assessment in the
lacebo group compared with a positive effect in all BG9928
roups. Changes in NYHA functional class from baseline to
ay 10 occurred in 1 placebo patient who worsened by 1
evel and 5 BG9928-treated patients, each improved by 1
evel.
harmacokinetics. Pharmacokinetic parameters are sum-
arized in Table 3. BG9928 was rapidly absorbed, with a
max of 1.5 to 3.1 h. The Cmax, t1/2, and drug clearance were
enerally similar within doses for days 1, 6, and 10.
ignificant increases in AUC were observed at all dose levels
etween days 1 and 6, with no significant increases between
ays 6 and 10, suggesting that a steady state was reached by
ay 6. In general, BG9928 Cmax and AUC values increased
inearly with dose. Steady-state AUC values showed mod-
rate nonlinearity for the 75-mg dose. Elimination half-life
anged from 8 to 16 h after a single dose and from 14 to 25 h
n day 10 (steady state), which is consistent with once-daily
osing.
afety assessments. The incidence of adverse events was
Figure 5 Change in Body Weight During Dosing
Average change in body weight (kg) from baseline
to day 11 after placebo or BG9928 administration. n  10/group.ot higher among patients who received BG9928 compared
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August 14, 2007:600–6 Oral BG9928 in HFith those who received placebo, and no apparent dose-
elated effects were observed. The most frequently reported
dverse event in all patients during this study was asymp-
omatic orthostatic hypotension, which occurred in 3 pa-
ients (30%) given placebo compared with 8 of 40 patients
20%) who received any dose of BG9928. Other commonly
eported adverse events are shown in Table 4. Most
reatment-emergent adverse events were mild or moderate
n severity. Two serious adverse events were reported. One
atient who received BG9928 3 mg had a cerebral infarction
hat occurred 11 days after the last dose of study drug and
as classified as moderate in severity. The patient had a
revious history that included stroke, cerebral artery occlu-
ion, carotid endarterectomy, and coronary artery disease.
nother patient with a prior history of atrial fibrillation had
one-time recurrence on day 6 of administration of 15 mg
f BG9928. No significant changes in blood pressure were
eported in any patient in this study. No clinically significant
hanges in laboratory or ECG findings were observed.
iscussion
ral dosages of BG9928 (3 to 225 mg per day) were
ssociated with increased cumulative sodium excretion on
harmacokinetic Parameters on Days 1, 6, and 10
Table 3 Pharmacokinetic Parameters on Days 1, 6, and 10
Day 3 mg (n  10)
AUC(0–), ng·h/ml 1 395
6 455
10 567
Peak plasma concentration, ng/ml 1 59.9
6 69.5
10 70.8
Half-life, h 1 11.7
6 9.8
10 16.4
Drug clearance, ml/h/kg 1 95.8
6 84.2
10 73.1
ata presented are means.
AUC  area under the concentration time curve.
dverse Events Reported by at Least 2 Patients (20%) in Any BG9
Table 4 Adverse Events Reported by at Least 2 Patients (20%)
BG9928
3 mg (n  10) 15 mg (n  10)
Patients with an event 8 (80) 7 (70)
Adverse events
Orthostatic
hypotension
5 1
Dizziness 0 2
Nausea 2 2
Fatigue 0 0
Headache 0 2Lower-limb edema 2 0ay 1, and in some doses on day 6, when administered to
atients with HF caused by systolic dysfunction. These
oses were associated with, at most, mild increases in
otassium excretion without adversely affecting renal func-
ion. The incidence of adverse events was similar to placebo,
nd higher doses of BG9928 were not associated with an
ncrease in adverse events.
The pharmacokinetic profile of BG9928 was consistent
ith once-daily dosing, and dose-proportional pharmaco-
inetics were displayed over the entire dose range. No
vidence of drug accumulation was seen after the 10-day
osing period, and steady-state concentrations were
chieved by day 6.
Clinically relevant significant responses associated with
G9928 administration observed in this study included
ncreased natriuresis without change in renal function.
mportantly, these results were observed early and were
aintained at 6 days, although linear trends in dose-
ependent natriuresis were not observed subsequent to
osing day 1. At any given time point, maximal observed
ffects on sodium excretion and urine volume were achieved
t submaximal doses (i.e., 3, 15, or 75 mg); however, there
as no statistical evidence for a lesser effect at higher doses.
BG9928 Dose
15 mg (n  10) 75 mg (n  10) 225 mg (n  10)
1,925 12,111 27,270
2,432 18,334 36,732
2,612 17,469 39,876
339 1,973 4,474
364 1,922 4,838
395 1,811 5,209
7.9 11.8 8.3
9.2 11.4 10.3
9.9 12.9 13.8
87.8 78.1 75.2
74.1 56.7 57.9
72.3 56.2 58.3
roup
ny BG9928 Group
Total BG9928
(n  40)
Placebo
(n  10)g (n  10) 225 mg (n  10)
6 (60) 8 (80) 29 (73) 9 (90)
2 0 8 3
2 2 6 0
0 1 5 1
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Oral BG9928 in HF August 14, 2007:600–6hange in urine volume showed a similar trend, although
gain there were no statistically significant differences
mong dosages. It seems likely that the response to BG9928
eaches a plateau at submaximal doses and that apparent
ariation at higher doses is not significant. However, we
annot exclude the possibility that the apparently decreasing
ffects at higher dosages may result from activity at adeno-
ine receptors other than the A1 type. In addition, at each
ose used, maximal natriuretic and diuretic effects generally
ccurred early in the course of daily therapy (i.e., on day 1),
ith diminishing results thereafter. It is likely that differ-
nces in natriuresis observed between initial and subsequent
G9928 doses reflected differences in sodium intake before
nd after hospital admission for study participation, where
ietary intake was restricted.
The effects of BG9928 occurred in patients who were
eceiving standard therapies for HF, including ACE inhib-
tors, ARBs, and diuretics that can adversely affect renal
unction and electrolyte balance (4). A sustained period of
atriuresis and diuresis above baseline occurred over the 10
ays of dosing with BG9928. A common physiological
esponse to heightened sodium excretion, as occurs with
iuresis, is a compensatory decrease in glomerular filtration
ate. The lack of a decline in renal function in the presence
f a significantly greater diuresis suggests that BG9928 was
ot detrimental to and may have had a protective effect on
enal function. In addition, the minor kaliuresis that was
bserved is consistent with the site of action of BG9928 on
he distal tubule (3,14,15).
This first published study of multiple doses of an oral
elective A1 adenosine receptor antagonist in humans shows
rends toward beneficial effects in clinical measures of HF,
ncluding body weight, edema, and physician global assess-
ent in patients who received BG9928 for 10 days. Al-
hough statistical significance was not reached for the
utcomes, the findings are noteworthy because the treat-
ent period was relatively short and the effects occurred in
ombination with standard therapy in patients with stable
isease. The results are consistent with prior clinical studies
ith single intravenous doses of a different A1 adenosine
ntagonist (BG9719), which showed natriuretic and renal
rotective effects in HF patients treated with standard
herapy (3,14). Future studies that include larger numbers of
atients will assess these effects more rigorously. Studies also
re planned to investigate short-term intravenous treatment
ith BG9928 in acutely decompensated HF patients receiv-
ng intravenous diuretics. Continued research is also neces-
ary to fully assess the safety profile of BG9928. In addition,
he absence of renal function decline in the present study in
oth treatment and placebo-control groups prohibits a
efinite conclusion regarding potential renal-protective ef-
ects of BG9928 in this sample of HF patients. Longer-
erm studies with the oral formulation are planned to detectny renal protective effects, as well as effects on morbidity
nd mortality.
Oral doses of BG9928 (3 to 225 mg daily) for 10 days
roduced the desired physiological responses, and no safety
oncerns were observed. Additional studies of BG9928 are
arranted in patients with HF in whom natriuresis, volume
oss, and maintenance of renal function are desired.
cknowledgment
he authors thank Thomson Scientific Connexions for
heir editorial assistance.
eprint requests and correspondence: Dr. Barry Greenberg,
dvanced Heart Failure Treatment Program, University of
alifornia–San Diego, 200 West Arbor Drive-8411, San Diego,
alifornia 92103-8411. E-mail: bgreenberg@ucsd.edu.
EFERENCES
1. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal
dysfunction during intensive therapy for advanced chronic heart
failure. Am Heart J 1999;138:285–90.
2. Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium
retention of congestive heart failure. Arch Intern Med 1994;154:
1905–14.
3. Gottlieb SS, Skettino SL, Wolff A, et al. Effects of BG9719 (CVT-
124), an A1-adenosine receptor antagonist, and furosemide on glo-
merular filtration rate and natriuresis in patients with congestive heart
failure. J Am Coll Cardiol 2000;35:56–9.
4. Maxwell AP, Ong HY, Nicholls DP. Influence of progressive renal
dysfunction in chronic heart failure. Eur J Heart Fail 2002;4:125–30.
5. Krumholz HM, Chen Y-T, Vaccarino V, et al. Correlates and impact
on outcomes of worsening renal function in patients 65 years of age
with heart failure. Am J Cardiol 2000;85:1110–3.
6. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in
the general population: the Rotterdam Study. Eur Heart J 2001;22:
1318–27.
7. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance
of different definitions of worsening renal function in congestive heart
failure. J Card Fail 2002;8:136–41.
8. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at
admission, and impact of worsening renal function among patients
hospitalised with heart failure. J Am Coll Cardiol 2004;43:61–7.
9. Butler J, Forman DE, Abraham WT, et al. Relationship between heart
failure treatment and development of worsening renal function among
hospitalised patients. Am Heart J 2004;147:331–8.
0. Fonarow GC, Adams KF Jr., Abraham WT, Yancy CW, Boscardin
WJ, ADHERE Scientific Advisory Committee, Study Group, and
Investigators. Risk stratification for in-hospital mortality in acutely
decompensated heart failure: classification and regression tree analysis.
JAMA 2005;293:572–80.
1. Edlund A, Ohlsén H, Sollevi A. Renal effects of local infusion of
adenosine in man. Clin Sci (Lond) 1994;87:143–9.
2. Marraccini P, Fedele S, Marzilli M, et al. Adenosine-induced renal
vasoconstriction in man. Cardiovasc Res 1996;32:949–53.
3. Munger KA, Jackson EK. Effects of selective A1 receptor blockade on
glomerular hemodynamics: involvement of renin-angiotensin system.
Am J Physiol 1994;267:F783–90.
4. Gottlieb S, Brater C, Thomas I, et al. BG9719 (CVT-124), an A1
adenosine receptor antagonist, protects against the decline in renal
function observed with diuretic therapy. Circulation 2002;105:
1348–53.
5. Ticho B, Whalley E, Gill A, et al. Renal effects of BG8828, an A1
adenosine receptor antagonist, in rats and nonhuman primates. Drug
Dev Res 2003;58:486–92.
